Publications by authors named "Richard Alonso"

Claim this Profile
F
Further evidence for the sleep-promoting effects of 5-HT₂A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats.
Guy Griebel, Sandra Beeské, Agnès Jacquet, Christian Laufrais, Richard Alonso

Neuropharmacology· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia.
Denis Boulay, Philippe Pichat, Gihad Dargazanli, Genevieve Estenne-Bouhtou, Jean Paul Terranova, Richard Alonso

Pharmacol Biochem Behav· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.
Jeanne Stemmelin, Caroline Cohen, Jean-Paul Terranova, Matilde Lopez-Grancha, Philippe Pichat, Richard Alonso

Neuropsychopharmacology· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.
Ronan Depoortère, Gihad Dargazanli, Genevieve Estenne-Bouhtou, Annick Coste, Christophe Lanneau, Richard Alonso

Neuropsychopharmacology· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior.
Christine Duarte, Richard Alonso, Nicole Bichet, Caroline Cohen, Philippe Soubrié

Neuropsychopharmacology· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization.
Jean Gougat, Bernard Ferrari, Lionel Sarran, Claudine Planchenault, Martine Poncelet, Richard Alonso

J Pharmacol Exp Ther· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.
Yves Claustre, Danielle De Peretti, Philippe Brun, Christiane Gueudet, Nathalie Allouard, Richard Alonso

Neuropsychopharmacology· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization.
Régis Steinberg, Richard Alonso, Liliane Rouquier, Christophe Desvignes, Jean-Claude Michaud

J Pharmacol Exp Ther· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis